Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1973 May;28(3):331–334. doi: 10.1136/thx.28.3.331

Effects of a new cardioselective beta-adrenergic blocker (tolamolol) on exercise tolerance in patients with angina pectoris

N K Sood 1, C W H Havard 1
PMCID: PMC470037  PMID: 4146782

Abstract

The effect of oral and intravenous tolamolol on exercise tolerance was assessed in 11 patients with angina pectoris. Patients were selected on the basis of an absence of placebo response and the reliable reproducibility of anginal pain and electrocardiographic changes with exercise on a constant load Schönander-Elema bicycle ergometer. The effect of tolamolol on exercise time and heart rate was compared with that of propranolol. Tolamolol was shown to increase exercise tolerance and the effect was comparable to that of propranolol. Tolamolol did not produce a significant increase in airways resistance nor were any untoward side effects noted.

Full text

PDF
331

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. APTHORP G. H., CHAMBERLAIN D. A., HAYWARD G. W. THE EFFECTS OF SYMPATHECTOMY ON THE ELECTROCARDIOGRAM AND EFFORT TOLERANCE IN ANGINA PECTORIS. Br Heart J. 1964 Mar;26:218–226. doi: 10.1136/hrt.26.2.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Areskog N. H., Adolfsson L. Effects of a cardio-selective beta-adrenergic blocker (I.C.I. 50172) at exercise in angina pectoris. Br Med J. 1969 Jun 7;2(5657):601–603. doi: 10.1136/bmj.2.5657.601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cole R. E., Goldberg R. I. Timed-release pentaerythritol tetranitrate and placebo in the management of angina pectoris. Curr Ther Res Clin Exp. 1967 Nov;9(11):551–557. [PubMed] [Google Scholar]
  4. DORNHORST A. C., ROBINSON B. F. Clinical pharmacology of a beta-adrenergic-blocking agent (Nethalide). Lancet. 1962 Aug 18;2(7251):314–316. doi: 10.1016/s0140-6736(62)90104-6. [DOI] [PubMed] [Google Scholar]
  5. Datey K. K., Dalvi C. P. Anti anginal drugs, their evaluation by double blind trial. Angiology. 1970 Sep;21(8):520–525. doi: 10.1177/000331977002100804. [DOI] [PubMed] [Google Scholar]
  6. Dunlop D., Shanks R. G. Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother. 1968 Jan;32(1):201–218. doi: 10.1111/j.1476-5381.1968.tb00444.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. GILLAM P. M., PRICHARD B. N. USE OF PROPRANOLOL IN ANGINA PECTORIS. Br Med J. 1965 Aug 7;2(5457):337–339. doi: 10.1136/bmj.2.5457.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gibson D., Sowton E. Effects of I.C.I. 50172 in man during erect exercise. Br Med J. 1968 Jan 27;1(5586):213–215. doi: 10.1136/bmj.1.5586.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. HAMER J., GRANDJEAN T., MELENDEZ L., SOWTON G. E. EFFECT OF PROPRANOLOL (INDERAL) IN ANGINA PECTORIS: PRELIMINARY REPORT. Br Med J. 1964 Sep 19;2(5411):720–723. doi: 10.1136/bmj.2.5411.720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hamer J., Sowton E. Effects of propranolol on exercise tolerance in angina pectoris. Am J Cardiol. 1966 Sep;18(3):354–360. doi: 10.1016/0002-9149(66)90053-1. [DOI] [PubMed] [Google Scholar]
  11. MCNEILL R. S. EFFECT OF A BETA-ADRENERGIC-BLOCKING AGENT, PROPRANOLOL, ON ASTHMATICS. Lancet. 1964 Nov 21;2(7369):1101–1102. doi: 10.1016/s0140-6736(64)92617-0. [DOI] [PubMed] [Google Scholar]
  12. PRICHARD B. N., DICKINSON C. J., ALLEYNE G. A., HURST P., HILL I. D., ROSENHEIM M. L., LAURENCE D. R. EFFECT OF PRONETHALOL IN ANGINA PECTORIS. Br Med J. 1963 Nov 16;2(5367):1226–1229. doi: 10.1136/bmj.2.5367.1226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Redwood D. R., Rosing D. R., Goldstein R. E., Beiser G. D., Epstein S. E. Importance of the design of an exercise protocol in the evaluation of patients with angina pectoris. Circulation. 1971 May;43(5):618–628. doi: 10.1161/01.cir.43.5.618. [DOI] [PubMed] [Google Scholar]
  14. Sandler G., Clayton G. A. Clinical evaluation of practolol, a new cardioselective beta-blocking agent in angina pectoris. Br Med J. 1970 May 16;2(5706):399–402. doi: 10.1136/bmj.2.5706.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sowton E., Balcon R., Cross D., Frick H. Haemodynamic effects of I.C.I. 50172 in patients with ischaemic heart disease. Br Med J. 1968 Jan 27;1(5586):215–216. doi: 10.1136/bmj.1.5586.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Stephen S. A. Unwanted effects of propranolol. Am J Cardiol. 1966 Sep;18(3):463–472. doi: 10.1016/0002-9149(66)90071-3. [DOI] [PubMed] [Google Scholar]
  17. Wilson D. F., Turner A. S. Trasicor (39,089/Ba) in angina pectoris. A single-blind trial. N Z Med J. 1968 Mar;67(430):406–407. [PubMed] [Google Scholar]
  18. Wilson D. F., Watson O. F., Peel J. S., Langley R. B., Turner A. S. Some haemodynamic effects of trasicor (Ciba 39,089-Ba). N Z Med J. 1968 Sep;68(436):145–149. [PubMed] [Google Scholar]
  19. Wilson D. F., Watson O. F., Peel J. S., Turner A. S. Trasicor in angina pectoris: a double-blind trial. Br Med J. 1969 Apr 19;2(5650):155–157. doi: 10.1136/bmj.2.5650.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wolfson S., Heinle R. A., Herman M. V., Kemp H. G., Sullivan J. M., Gorlin R. Propranolol and angina pectoris. Am J Cardiol. 1966 Sep;18(3):345–353. doi: 10.1016/0002-9149(66)90052-x. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES